Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
All business segments reported higher sales. The wholesale of prescription pharmaceuticals and related products business recorded higher sales and income due to increased demand, stronger sales, and higher sales through dispensing pharmacies. The wholesale of cosmetics, daily necessities and related products business recorded higher sales due to higher selling prices, but lower income due to increases in rebates and center fees, personnel expenses and logistics expenses. The wholesale of veterinary pharmaceuticals and food-processing raw materials, and related businesses segment recorded higher sales and income following the consolidation of シグニ. At the company-wide level, net income increased due to gains on sales of investment securities.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥989,503 million (YoY +4.7%) |
| Operating profit | ¥13,386 million (YoY -4.7%) |
| Ordinary income | ¥17,919 million (YoY -1.7%) |
| Profit attributable to owners of the parent | ¥13,646 million (YoY +42.3%) |
| Net income per share | 66.67 |
| Equity ratio | End of the current fiscal period 33.5 / End of previous period 33.9 |
| Total assets | ¥1,937,423 million |
| Net assets | ¥791,716 million |
| Full-year earnings forecast | Net Sales ¥3,944,000 million (YoY +3.3%) / Operating profit ¥53,500 million (YoY +0.6%) / Ordinary income ¥67,500 million (YoY -10.9%) / Profit attributable to owners of the parent ¥43,000 million (YoY +1.1%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | 66 yen and sen → 88 yen and sen |
| Segment revenue | Wholesale business for prescription pharmaceuticals and other products ¥630,556 million (YoY +5.1%), Wholesale business for cosmetics, daily necessities and over-the-counter pharmaceuticals ¥326,927 million (YoY +3.4%), Related businesses, including wholesale of veterinary pharmaceuticals and food-processing raw materials ¥33,094 million (YoY +9.9%) |
| Segment profit | Wholesale business for prescription pharmaceuticals and other products ¥6,303 million (YoY +13.9%), Wholesale business for cosmetics, daily necessities and over-the-counter pharmaceuticals ¥6,134 million (YoY -19.5%), Related businesses, including wholesale of veterinary pharmaceuticals and food-processing raw materials ¥1,071 million (YoY +39.9%) |
| Depreciation and amortization | ¥4,518 million |
| Impairment loss | ¥0 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥148 million, Gain on sale of investment securities ¥6,061 million, Other ¥1 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥19 million, Impairment Losses ¥0 million, Impairment Loss on Investment Securities ¥410 million, Other ¥1 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Name of newly added company Not disclosed / Excluded Company Name Not disclosed |
| Material subsequent events | The tender offer for PALTAC shares ended on 7 July 2026, and a ¥162.7 billion bridge loan was drawn on 13 July 2026 to fund the tender offer. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 215,975,042 |
| Treasury Shares at Period-End | 11,276,654 |
| Factors Behind Changes in Business Performance | All business segments reported higher sales. The wholesale of prescription pharmaceuticals and related products business recorded higher sales and income due to increased demand, stronger sales, and higher sales through dispensing pharmacies. The wholesale of cosmetics, daily necessities and related products business recorded higher sales due to higher selling prices, but lower income due to increases in rebates and center fees, personnel expenses and logistics expenses. The wholesale of veterinary pharmaceuticals and food-processing raw materials, and related businesses segment recorded higher sales and income following the consolidation of シグニ. At the company-wide level, net income increased due to gains on sales of investment securities. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased due to higher demand for products covered by the innovative new drug pricing maintenance system, stronger sales of growth products, higher sales through dispensing pharmacies, the acquisition of new billing arrangements, and an expanded range of products handled. Operating income decreased due to changes in the product mix, higher rebates and center fees paid to customers, and increases in personnel and logistics expenses. Net income attributable to owners of the parent increased as extraordinary income and losses improved, mainly due to gains on sales of investment securities.